In this single-center, open-label, no control, prospective clinical trial, a total of 10
relapsed or refractory CD19 positive B-cell Non-Hodgkin Lymphoma (NHL) patients will be
enrolled.CD19 CAR T cells(total dose of 2×10^6/kg-1×10^7/kg) will be intravenously infused to
patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2. The
purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells
in patients with relapsed or refractory CD19 positive B-cell lymphoma.